Mauricio Catala
Overview
Explore the profile of Mauricio Catala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suarez G, Catala M, Pena Y, Portela S, Ane-Kouri A, Gonzalez A, et al.
Front Oncol
. 2022 Feb;
12:823287.
PMID: 35155258
Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations....
2.
Suarez G, Ane-Kouri A, Gonzalez A, Lorenzo-Luaces P, Neninger E, Salomon E, et al.
Cancer Immunol Immunother
. 2021 Jan;
70(6):1735-1743.
PMID: 33388995
Aging is considered the single most significant risk factor for the majority of common malignances including lung cancer. Together immunosenescence, changes occurring with aging in the immune system, and inflammaging,...
3.
Rodriguez P, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, et al.
Clin Cancer Res
. 2016 Mar;
22(15):3782-90.
PMID: 26927662
Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein...
4.
Solomon M, Selva J, Figueredo J, Vaquer J, Toledo C, Quintanal N, et al.
BMC Cancer
. 2013 Jun;
13:299.
PMID: 23782513
Background: The prognosis of patients bearing high grade glioma remains dismal. Epidermal Growth Factor Receptor (EGFR) is well validated as a primary contributor of glioma initiation and progression. Nimotuzumab is...
5.
Crombet Ramos T, Figueredo J, Catala M, Gonzalez S, Selva J, Cruz T, et al.
Cancer Biol Ther
. 2006 Apr;
5(4):375-9.
PMID: 16575203
The poor prognosis of patients with high-grade glioma has led to the search for new therapeutic strategies. More than half of these tumors overexpress Epidermal Growth factor Receptor (EGFR). h-R3...
6.
Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, et al.
Clin Immunol
. 2003 May;
107(2):80-9.
PMID: 12763476
A phase I clinical trial was conducted in patients with stage III/IV breast cancer who were treated with the anti-idiotype mAb 1E10 specific to an Ab1 mAb able to react...
7.
Crombet T, Torres L, Neninger E, Catala M, Solano M, Perera A, et al.
J Immunother
. 2003 Mar;
26(2):139-48.
PMID: 12616105
Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epithelial origin, and it is often associated with tumor growth advantages and poor prognosis. h-R3 is a...